121 related articles for article (PubMed ID: 11111224)
21. Immunohistochemical labelling of steroid receptors in normal and malignant human endometrium.
Mylonas I; Makovitzky J; Friese K; Jeschke U
Acta Histochem; 2009; 111(4):349-59. PubMed ID: 19195687
[TBL] [Abstract][Full Text] [Related]
22. Expression of estrogen receptors alpha and beta, and progesterone receptors A and B in human mucinous carcinoma of the endometrium.
Shabani N; Mylonas I; Jeschke U; Thaqi A; Kuhn C; Puchner T; Friese K
Anticancer Res; 2007; 27(4A):2027-33. PubMed ID: 17649817
[TBL] [Abstract][Full Text] [Related]
23. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.
Oreskovic S; Babic D; Kalafatic D; Barisic D; Beketic-Oreskovic L
Gynecol Oncol; 2004 Apr; 93(1):34-40. PubMed ID: 15047211
[TBL] [Abstract][Full Text] [Related]
24. Expression of uteroglobin in normal and carcinogenic endometrium and influence of hormone replacement therapy.
Tanaka R; Saito T; Shijubo N; Takehara M; Yamada G; Kawabata I; Itoh Y; Kudo R
Int J Cancer; 2004 Mar; 109(1):43-8. PubMed ID: 14735466
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of erythropoietin expression in human endometrial carcinoma.
Acs G; Xu X; Chu C; Acs P; Verma A
Cancer; 2004 Jun; 100(11):2376-86. PubMed ID: 15160341
[TBL] [Abstract][Full Text] [Related]
26. Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer.
Rahman MT; Nakayama K; Ishikawa M; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Iida K; Miyazaki K
Oncology; 2013; 84(3):166-73. PubMed ID: 23306391
[TBL] [Abstract][Full Text] [Related]
27. PTEN expression in breast and endometrial cancer: correlations with steroid hormone receptor status.
Kappes H; Goemann C; Bamberger AM; Löning T; Milde-Langosch K
Pathobiology; 2001; 69(3):136-42. PubMed ID: 11872959
[TBL] [Abstract][Full Text] [Related]
28. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma.
Li M; Zhao L; Shen D; Li X; Wang J; Wei L
Chin Med J (Engl); 2014; 127(8):1459-63. PubMed ID: 24762589
[TBL] [Abstract][Full Text] [Related]
29. Is the positivity of estrogen receptor or progesterone receptor different between type 1 and type 2 endometrial cancer?
Shen F; Gao Y; Ding J; Chen Q
Oncotarget; 2017 Jan; 8(1):506-511. PubMed ID: 27888807
[TBL] [Abstract][Full Text] [Related]
30. Heart and Neural Crest Derivatives Expressed Transcript 2 (HAND2): a novel biomarker for the identification of atypical hyperplasia and Type I endometrial carcinoma.
Buell-Gutbrod R; Cavallo A; Lee N; Montag A; Gwin K
Int J Gynecol Pathol; 2015 Jan; 34(1):65-73. PubMed ID: 25473755
[TBL] [Abstract][Full Text] [Related]
31. Impact of estrogen and progesterone receptor expression on the incidence of endometrial polyps.
Yan C; Xing C; Wei T; Zhou H; Wang H; Liu T; Gao J
Biomark Med; 2023 Nov; 17(21):881-887. PubMed ID: 38230984
[No Abstract] [Full Text] [Related]
32. Oestrogen regulated gene expression in normal and malignant endometrial tissue.
O'Toole SA; Dunn E; Sheppard BL; Sheils O; O'Leary JJ; Wuttke W; Seidlova-Wuttke D
Maturitas; 2005 Jun; 51(2):187-98. PubMed ID: 15917160
[TBL] [Abstract][Full Text] [Related]
33. Steroid receptor expression in endometria from women treated with tamoxifen.
Kommoss F; Karck U; Prömpeler H; Pfisterer J; Kirkpatrick CJ
Gynecol Oncol; 1998 Aug; 70(2):188-91. PubMed ID: 9740688
[TBL] [Abstract][Full Text] [Related]
34. Endometrial adenocarcinoma: beliefs and scepticism.
Sivridis E; Giatromanolaki A
Int J Surg Pathol; 2004 Apr; 12(2):99-105. PubMed ID: 15173914
[TBL] [Abstract][Full Text] [Related]
35. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
[TBL] [Abstract][Full Text] [Related]
36. Role of bcl-2 in endometrioid corpus cancer: an experimental study.
Mariani A; Sebo TJ; Cliby WA; Keeney GL; Riehle DL; Lesnick TG; Podratz KC
Anticancer Res; 2006; 26(2A):823-7. PubMed ID: 16619475
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Different Scoring Systems in the Assessment of Estrogen Receptor Status for Predicting Prognosis in Endometrial Cancer.
Wang Y; Ma X; Wang Y; Liu Y; Liu C
Int J Gynecol Pathol; 2019 Mar; 38(2):111-118. PubMed ID: 29406446
[TBL] [Abstract][Full Text] [Related]
38. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
[TBL] [Abstract][Full Text] [Related]
39. Proliferative activity in postmenopausal endometrium: the lurking potential for giving rise to an endometrial adenocarcinoma.
Sivridis E; Giatromanolaki A
J Clin Pathol; 2004 Aug; 57(8):840-4. PubMed ID: 15280405
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous carcinoma of the endometrium and ovary vs endometrial carcinoma with ovarian metastases: a clinical and immunohistochemical determination.
Halperin R; Zehavi S; Hadas E; Habler L; Bukovsky I; Schneider D
Int J Gynecol Cancer; 2003; 13(1):32-7. PubMed ID: 12631217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
